Pub. Date : 2010 Nov 1
PMID : 20959404
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 2 | Pretreatment with EGFR or PI3K inhibitor in TL-1 cells diminished the resistance to cisplatin. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 3 | CONCLUSIONS: cIAP2 upregulated by E6 via EGFR/PI3K/AKT cascades may contribute to cisplatin resistance, revealing that the EGFR or PI3K inhibitor combined with cisplatin may improve the chemotherapeutic efficacy in HPV-infected lung cancer. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 4 | CONCLUSIONS: cIAP2 upregulated by E6 via EGFR/PI3K/AKT cascades may contribute to cisplatin resistance, revealing that the EGFR or PI3K inhibitor combined with cisplatin may improve the chemotherapeutic efficacy in HPV-infected lung cancer. | Cisplatin | epidermal growth factor receptor | Homo sapiens |
| 5 | CONCLUSIONS: cIAP2 upregulated by E6 via EGFR/PI3K/AKT cascades may contribute to cisplatin resistance, revealing that the EGFR or PI3K inhibitor combined with cisplatin may improve the chemotherapeutic efficacy in HPV-infected lung cancer. | Cisplatin | epidermal growth factor receptor | Homo sapiens |